Teva Pharmaceutical Industries (TEVA) β†’ Stock, financial statements
Advertising

Teva Pharmaceutical Industries

7.89 USD -0.03 (-0.31%)
Jul 01 πŸ‡ΊπŸ‡Έ NYSE TEVA
Dividends News
Favorites
  • TEVA Ticker
  • πŸ‡ΊπŸ‡Έ NYSE Exchange
  • 42,535 Employees
4 rated
comming soon
comming soon
comming soon
comming soon
comming soon
comming soon
comming soon
comming soon
comming soon

Financial statements β€” Teva Pharmaceutical Industries

The information is not 100% up-to-date. There may be errors or missing information. Some information is often missing, and, although there are almost no errors, I can't rule them out. Right now, I'm looking for a supplier of high-quality information, but so far what I'm finding is expensive (about $2000 a year). You can help my project here.
20 ← 16 2020 2019 2018 2017 2016
Total Revenue
17B 17B 19B 22B 22B
Cost Of Revenue
8.9B 9.4B 11B 12B 10B
Gross Profit
7.7B 7.5B 8.3B 11B 12B
Research and Development
1M 1B 1.2B 1.8B 2.1B
Selling General and Admin
3.7B 3.8B 4.2B 5B 5.1B
Operating Expense
14B 14B 16B 18B 17B
Operating Income
3.1B 2.7B 2.9B 4B 4.7B
Other Income Expense Net
0 0 0 0 0
EBIT
3.2B 2.7B 2.8B 4B 4.7B
Interest Income
960M 880M 920M 880M 550M
Pretax Income
-4.3B -1.3B -2.7B -18B 830M
Income Tax
-170M -280M -200M -1.9B 520M
Minority Interest
-110M -2M -320M -180M -18M
Net Income
-4B -1M -2.4B -17B 68M
Net Income Basic
-4B -1M -2.4B -17B 68M
20 ← 16 2020 2019 2018 2017 2016
Current cash
2.2B 2B 1.8B 980M 1.7B
Short term investments
1.7B 1.3B 1.4B 1.8B 2B
Receivables
4.6B 5.7B 5.8B 7.1B 7.5B
Inventory
4.4B 4.4B 4.7B 4.9B 5B
Other current assets
1.7B 1.3B 1.4B 1.8B 2B
Current assets
13B 13B 14B 15B 17B
Long term investments
38B 44B 47B 55B 76B
Property plant equipment
6.3B 6.4B 6.9B 7.7B 8.1B
Goodwill
21B 25B 25B 28B 44B
Intangible assets
8.9B 11B 14B 18B 21B
Other assets
540M 590M 670M 850M 950M
Total assets
51B 57B 61B 71B 93B
Accounts payable
1.8B 1.7B 1.9B 2.1B 2.2B
Current long term debt
3.2B 2.3B 2.2B 3.6B 3.3B
Other current liabilities
8.2B 9.6B 10B 12B 13B
Total current liabilities
13B 14B 14B 18B 19B
Long term debt
23B 25B 27B 29B 33B
Other liabilities
2.2B 2.6B 1.7B 1.8B 1.6B
Minority Interest
1B 1.1B 1.1B 1.4B 1.7B
Total Liabilities
41B 43B 46B 53B 60B
Common stock
1.1B 1.1B 1B 1B 960M
Retained earning
-11B -7B -6B -3.8B 14B
Treasury stock
-4.1B -4.1B -4.1B -4.1B -4.2B
Capital surplus
β€’ β€’ β€’ β€’ β€’
Shareholder equity
10B 14B 15B 17B 33B
Net tangible assets
-20B -22B -24B -32B -36B
20 ← 16 2020 2019 2018 2017 2016
Net Income
-4B -1M -2.4B -17B 68M
Depreciation
1.6B 1.7B 1.8B 2.1B 1.5B
Changes in receivables
-1.1B -150M -1.3B -400M 2.2B
Changes in inventories
-18M -310M -190M -30M 990M
Cash change
200M 190M 810M -690M -5.3B
Cash flow
1.2B 750M 2.4B 3.5B 5.2B
Capital expenditures
-580M -530M -650M -870M -900M
Investments
β€’ β€’ β€’ β€’ β€’
Investing activity other
β€’ β€’ β€’ β€’ β€’
Total investing cash flows
860M 1.4B 1.9B 2.2B -36B
Dividends paid
β€’ β€’ β€’ β€’ β€’
Net borrowings
22B 24B 26B 30B 32B
Other financing cash flows
β€’ β€’ β€’ β€’ β€’
Cash flow financing
-1.9B -1.9B -3.4B -5.8B 25B
Exchange rate effect
β€’ β€’ β€’ β€’ β€’

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company, which engages in development, production and marketing of drugs, generic drugs, over-the-counter drugs, active ingredients for the pharmaceutical industry (APIs) and therapeutic products. It operates through two segments: Generic Medicines and Specialty Medicines. The Generic Medicines segment includes chemical and therapeutic equivalents of originator medicines in a variety of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. The Specialty Medicine segment engages in the provision of core therapeutic areas of central nervous system medicines. The company was founded in 1901 and is headquartered in Petach Tikva, Israel.